Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma

Michael Roth, Marissa Linkowski, John Tarim, Sajida Piperdi, Rebecca Sowers, David S. Geller, Jonathan Gill, Richard Gorlick

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

BACKGROUND Survival outcomes for patients with osteosarcoma have remained stagnant over the past 30 years. Targeting of ganglioside GD2, a glycosphingolipid on the cell surface of some tumors, with immunotherapy has resulted in improved outcomes for patients with neuroblastoma. In the current study, the expression pattern of GD2 was examined in osteosarcoma. METHODS Immunohistochemistry was performed on osteosarcoma samples from patients at the time of initial biopsy, definitive surgery, and disease recurrence. The intensity and location of staining were scored. Cell-based enzyme-linked immunoadsorbent assay was performed on osteosarcoma cell lines to quantitate the level of GD2 expression. RESULTS Forty-four osteosarcoma samples were evaluated by immunohistochemistry, including 8 samples from the initial biopsy, 28 samples from the definitive surgery, and 8 samples from the time of disease recurrence. GD2 was expressed on all 44 osteosarcoma samples. Osteosarcoma tissue obtained at the time of disease recurrence demonstrated a higher intensity of staining compared with samples obtained at initial biopsy and definitive surgery (P =.016). The majority of osteosarcoma cell lines expressed GD2 at higher levels than the neuroblastoma cell line BE(2)-C. CONCLUSIONS Ganglioside GD2 is highly expressed on osteosarcomas. Clinical trials are needed to assess the efficacy of targeting GD2 in patients with osteosarcoma. Cancer 2014;120:548-554.

Original languageEnglish (US)
Pages (from-to)548-554
Number of pages7
JournalCancer
Volume120
Issue number4
DOIs
StatePublished - Feb 15 2014

Fingerprint

Osteosarcoma
Antibodies
Therapeutics
Neuroblastoma
Biopsy
Recurrence
Cell Line
Immunohistochemistry
GD2 ganglioside
Staining and Labeling
Glycosphingolipids
Immunosorbents
Immunotherapy
Neoplasms
Clinical Trials
Survival

Keywords

  • antibody
  • ganglioside GD2
  • immunotherapy
  • osteosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Roth, M., Linkowski, M., Tarim, J., Piperdi, S., Sowers, R., Geller, D. S., ... Gorlick, R. (2014). Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer, 120(4), 548-554. https://doi.org/10.1002/cncr.28461

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. / Roth, Michael; Linkowski, Marissa; Tarim, John; Piperdi, Sajida; Sowers, Rebecca; Geller, David S.; Gill, Jonathan; Gorlick, Richard.

In: Cancer, Vol. 120, No. 4, 15.02.2014, p. 548-554.

Research output: Contribution to journalArticle

Roth, M, Linkowski, M, Tarim, J, Piperdi, S, Sowers, R, Geller, DS, Gill, J & Gorlick, R 2014, 'Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma', Cancer, vol. 120, no. 4, pp. 548-554. https://doi.org/10.1002/cncr.28461
Roth, Michael ; Linkowski, Marissa ; Tarim, John ; Piperdi, Sajida ; Sowers, Rebecca ; Geller, David S. ; Gill, Jonathan ; Gorlick, Richard. / Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. In: Cancer. 2014 ; Vol. 120, No. 4. pp. 548-554.
@article{c48972b84bb849428ebcb248180d392d,
title = "Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma",
abstract = "BACKGROUND Survival outcomes for patients with osteosarcoma have remained stagnant over the past 30 years. Targeting of ganglioside GD2, a glycosphingolipid on the cell surface of some tumors, with immunotherapy has resulted in improved outcomes for patients with neuroblastoma. In the current study, the expression pattern of GD2 was examined in osteosarcoma. METHODS Immunohistochemistry was performed on osteosarcoma samples from patients at the time of initial biopsy, definitive surgery, and disease recurrence. The intensity and location of staining were scored. Cell-based enzyme-linked immunoadsorbent assay was performed on osteosarcoma cell lines to quantitate the level of GD2 expression. RESULTS Forty-four osteosarcoma samples were evaluated by immunohistochemistry, including 8 samples from the initial biopsy, 28 samples from the definitive surgery, and 8 samples from the time of disease recurrence. GD2 was expressed on all 44 osteosarcoma samples. Osteosarcoma tissue obtained at the time of disease recurrence demonstrated a higher intensity of staining compared with samples obtained at initial biopsy and definitive surgery (P =.016). The majority of osteosarcoma cell lines expressed GD2 at higher levels than the neuroblastoma cell line BE(2)-C. CONCLUSIONS Ganglioside GD2 is highly expressed on osteosarcomas. Clinical trials are needed to assess the efficacy of targeting GD2 in patients with osteosarcoma. Cancer 2014;120:548-554.",
keywords = "antibody, ganglioside GD2, immunotherapy, osteosarcoma",
author = "Michael Roth and Marissa Linkowski and John Tarim and Sajida Piperdi and Rebecca Sowers and Geller, {David S.} and Jonathan Gill and Richard Gorlick",
year = "2014",
month = "2",
day = "15",
doi = "10.1002/cncr.28461",
language = "English (US)",
volume = "120",
pages = "548--554",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma

AU - Roth, Michael

AU - Linkowski, Marissa

AU - Tarim, John

AU - Piperdi, Sajida

AU - Sowers, Rebecca

AU - Geller, David S.

AU - Gill, Jonathan

AU - Gorlick, Richard

PY - 2014/2/15

Y1 - 2014/2/15

N2 - BACKGROUND Survival outcomes for patients with osteosarcoma have remained stagnant over the past 30 years. Targeting of ganglioside GD2, a glycosphingolipid on the cell surface of some tumors, with immunotherapy has resulted in improved outcomes for patients with neuroblastoma. In the current study, the expression pattern of GD2 was examined in osteosarcoma. METHODS Immunohistochemistry was performed on osteosarcoma samples from patients at the time of initial biopsy, definitive surgery, and disease recurrence. The intensity and location of staining were scored. Cell-based enzyme-linked immunoadsorbent assay was performed on osteosarcoma cell lines to quantitate the level of GD2 expression. RESULTS Forty-four osteosarcoma samples were evaluated by immunohistochemistry, including 8 samples from the initial biopsy, 28 samples from the definitive surgery, and 8 samples from the time of disease recurrence. GD2 was expressed on all 44 osteosarcoma samples. Osteosarcoma tissue obtained at the time of disease recurrence demonstrated a higher intensity of staining compared with samples obtained at initial biopsy and definitive surgery (P =.016). The majority of osteosarcoma cell lines expressed GD2 at higher levels than the neuroblastoma cell line BE(2)-C. CONCLUSIONS Ganglioside GD2 is highly expressed on osteosarcomas. Clinical trials are needed to assess the efficacy of targeting GD2 in patients with osteosarcoma. Cancer 2014;120:548-554.

AB - BACKGROUND Survival outcomes for patients with osteosarcoma have remained stagnant over the past 30 years. Targeting of ganglioside GD2, a glycosphingolipid on the cell surface of some tumors, with immunotherapy has resulted in improved outcomes for patients with neuroblastoma. In the current study, the expression pattern of GD2 was examined in osteosarcoma. METHODS Immunohistochemistry was performed on osteosarcoma samples from patients at the time of initial biopsy, definitive surgery, and disease recurrence. The intensity and location of staining were scored. Cell-based enzyme-linked immunoadsorbent assay was performed on osteosarcoma cell lines to quantitate the level of GD2 expression. RESULTS Forty-four osteosarcoma samples were evaluated by immunohistochemistry, including 8 samples from the initial biopsy, 28 samples from the definitive surgery, and 8 samples from the time of disease recurrence. GD2 was expressed on all 44 osteosarcoma samples. Osteosarcoma tissue obtained at the time of disease recurrence demonstrated a higher intensity of staining compared with samples obtained at initial biopsy and definitive surgery (P =.016). The majority of osteosarcoma cell lines expressed GD2 at higher levels than the neuroblastoma cell line BE(2)-C. CONCLUSIONS Ganglioside GD2 is highly expressed on osteosarcomas. Clinical trials are needed to assess the efficacy of targeting GD2 in patients with osteosarcoma. Cancer 2014;120:548-554.

KW - antibody

KW - ganglioside GD2

KW - immunotherapy

KW - osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84893720908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893720908&partnerID=8YFLogxK

U2 - 10.1002/cncr.28461

DO - 10.1002/cncr.28461

M3 - Article

C2 - 24166473

AN - SCOPUS:84893720908

VL - 120

SP - 548

EP - 554

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -